This post was originally published on this site
The pharma giant reported a profit per share of 67 cents on revenue of $12.7 billion, beating the analyst consensus for a profit per share of 57 cents on revenue of $12.08B. Overall, revenue fell 54% year-over-year amid a major decline in COVID-19-related sales.
Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We look forward to continuing our progress in the second half of 2023, driven by commercial execution, scientific innovation and our never-ending commitment to delivering breakthroughs for patients.”
The company sees full-year EPS at $3.35 on revenue of $68.5B. Analysts were looking for EPS of $3.01 on revenue of $61B.
